KUALA LUMPUR, Oct 3 — GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory syncytial virus (RSV), a common respiratory virus that can lead to lower respiratory tract disease (LRTD) and pneumonia in older adults.
It has been approved for older adults aged 60 and above in the country.
While RSV is a disease of all ages, in 2019, the impact of RSV in adults aged 60 years and older was significant, resulting in over 470,000 hospitalisations and 33,000 deaths in high-income countries.
Dr Alap Gandhi, Country Medical Director of GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) Malaysia and Brunei said, “Today’s announcement is a major step forward from a public health perspective as it allows us to deliver an RSV vaccine in Malaysia to protect older adults.
“We look forward to working with various stakeholders to ensure those at high risk of severe RSV infection can access it.”
Adults with underlying co-morbidities, including chronic obstructive pulmonary disease (COPD), asthma, diabetes, and chronic heart failure (CHF) are at high risk for severe RSV.
Since the Covid-19 pandemic, there has been an altered pattern of seasonal infections due to Covid-19 protection measures.
Specifically in Malaysia, RSV infections occur all year round, with notable peaks typically occurring between July to August, as well as October to December.
Professor Dr Ahmad Izuanuddin Ismail, Deputy Director & Consultant, Respiratory Physician Hospital Al Sultan Abdullah Universiti Teknologi MARA (HASA UiTM) said, “RSV can lead to severe outcomes especially among older adults with co-morbidities such as asthma, COPD and chronic heart failure.
“They also have an increased risk of hospitalisation following the RSV infection. It is important for us to protect patients aged 60 and above with co-morbidities.
“In Malaysia, according to the 2023 National Health Morbidity Survey (NHMS), more than half a million adults live with four co-morbidities.”
The approval for the vaccine is based on positive data from a phase III trial, where the vaccine demonstrated high overall vaccine efficacy of 82.6 per cent against LRTD.
A 94.6 per cent efficacy was observed against RSV-LRTD in adults with co-morbidities.
Across multiple studies, the vaccine was generally well tolerated with an acceptable safety profile.
Some adverse events observed were injection site pain, fatigue, myalgia, and headache. These were typically mild to moderate and lasting within a few days after vaccination.
